MedTrace Logo

The Prevelence of HBB c.93-21 G-A in β Thalassemia Patients

NCT05133388 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-01-31

No results posted yet for this study

Summary

* To design an amplification-refractory mutation system (ARMS) for the DNA diagnosis of the IVS I-110 (G\>A) \[HBB:c.93-21G˃A\] mutation.
* To detect the prevelence of the mutation among Assiut University Hospital patients.
* Phenotype/genotype correlation of the mutation.

Conditions

Interventions

GENETIC

ARMS PCR

ARMS PCR using primer pairs that only amplify individual alleles

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ola Afifi · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2024-06-30
Completion
2024-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05133388 on ClinicalTrials.gov